Tadalafil Overview, Dosing & Safety | Peptide Database

Tadalafil (Cialis)

PDE5 Inhibitor | Erectile Function & Blood Flow

Community Research

Join others researching Tadalafil — share findings, ask questions, and learn from real experiences

Tadalafil is a long-acting PDE5 inhibitor FDA-approved for erectile dysfunction (ED), benign prostatic hyperplasia (BPH), and pulmonary arterial hypertension (PAH). Its extended half-life of approximately 17.5 hours provides a therapeutic window of up to 36 hours, earning it the nickname 'the weekend pill.' Unlike shorter-acting PDE5 inhibitors, tadalafil is uniquely suited for daily low-dose use (2.5-5mg), which maintains steady-state plasma levels and allows for spontaneous sexual activity without timing constraints. Originally developed by ICOS Corporation and marketed by Eli Lilly as Cialis, tadalafil received FDA approval in 2003 for ED and has since become one of the most widely prescribed medications in its class. Beyond sexual health, tadalafil has gained attention for its cardiovascular and hemodynamic benefits, including improved endothelial function, reduced blood pressure, and enhanced exercise capacity.

Tadalafil selectively inhibits phosphodiesterase type 5 (PDE5), the enzyme responsible for degrading cyclic guanosine monophosphate (cGMP) in smooth muscle tissue. During sexual stimulation, nitric oxide (NO) is released in the corpus cavernosum, activating guanylate cyclase and increasing cGMP levels. Elevated cGMP causes smooth muscle relaxation in penile arteries and the corpus cavernosum, facilitating increased blood flow and erection. By blocking PDE5, tadalafil prolongs and amplifies this cGMP-mediated vasodilatory signaling cascade. PDE5 is also expressed in pulmonary vasculature, prostatic smooth muscle, and the bladder neck, which accounts for tadalafil's therapeutic effects in PAH and BPH/LUTS. Tadalafil has high selectivity for PDE5 over PDE6 (the retinal isoform), which contributes to its lower incidence of visual disturbances compared to sildenafil.

Molecular Data

Research Indications

First-line pharmacotherapy for ED of various etiologies including psychogenic, vasculogenic, and mixed. Effective in a broad range of patient populations including those with diabetes and post-prostatectomy.

Daily low-dose tadalafil maintains steady plasma levels, allowing for spontaneous sexual activity without the need to time dosing around intercourse.

FDA-approved at 5mg daily for treatment of BPH signs and symptoms, including urinary frequency, urgency, weak stream, and nocturia. Can be used alone or with alpha-blockers.

Relaxes smooth muscle in the prostate, bladder neck, and urethra via PDE5 inhibition, improving urinary flow and reducing symptom severity.

FDA-approved as Adcirca (40mg daily) for PAH (WHO Group 1) to improve exercise ability. Relaxes pulmonary vasculature and reduces right ventricular afterload.

Enhances NO-cGMP signaling in systemic vasculature, improving flow-mediated dilation and arterial compliance. May slow progression of endothelial dysfunction.

Modest systemic vasodilation produces small but clinically meaningful reductions in systolic and diastolic blood pressure, particularly in patients with mild hypertension.

Enhanced NO-mediated vasodilation may increase blood flow to working muscles during resistance training, producing a more pronounced pump effect. Evidence is largely anecdotal but mechanistically plausible.

Some evidence suggests PDE5 inhibition can improve exercise performance at altitude by reducing pulmonary artery pressure and improving oxygen delivery.

Dosing Protocols

Tadalafil is exclusively administered orally as film-coated tablets. It can be taken with or without food, as high-fat meals do not significantly affect absorption rate or extent. Two distinct dosing strategies exist: as-needed dosing for planned sexual activity, and daily low-dose for continuous coverage and BPH management.

As-needed ED (starting dose)

10mg

As needed, at least 30 min before sexual activity

Oral

As-needed ED (adjusted dose)

20mg

As needed, max once per 24 hours

Daily low-dose ED (initiation)

2.5mg

Once daily, same time each day

Daily low-dose ED (standard)

5mg

BPH / LUTS

Once daily

Combined ED and BPH

Performance / Pre-workout (conservative)

12.5mg

Twice per week (e.g., training days)

Performance / Pre-workout (standard)

Every other day (EOD)

Performance / Pre-workout (aggressive)

Pulmonary arterial hypertension (Adcirca)

40mg

Interactions

What to Expect

Side Effects & Safety

Common Side Effects

Headache (11-15% incidence, most common side effect)

Dyspepsia / indigestion (4-13%)

Back pain (3-9%, relatively unique to tadalafil among PDE5 inhibitors)

Myalgia / muscle aches (1-7%, thought to be related to PDE11 inhibition)

Nasal congestion / rhinitis (3-5%)

Flushing (1-4%)

Limb pain (1-3%)

Dizziness (1-2%)

Stop Signs - Discontinue if:

Priapism: erection lasting more than 4 hours -- seek emergency medical attention immediately to prevent permanent tissue damage

Sudden loss or decrease in vision in one or both eyes (possible NAION)

Sudden decrease or loss of hearing, with or without tinnitus and dizziness

Chest pain, angina, or symptoms of a cardiac event during or after sexual activity

Severe hypotension symptoms: fainting, severe dizziness, lightheadedness upon standing

Allergic reaction: difficulty breathing, throat swelling, severe rash

Contraindications

Concurrent use of any organic nitrate medication (absolute contraindication)

Concurrent use of guanylate cyclase stimulators (e.g., riociguat)

Known hypersensitivity to tadalafil or any tablet excipient

Severe hepatic impairment (Child-Pugh Class C)

Recent stroke or myocardial infarction (within 90 days)

Unstable angina or angina during sexual intercourse

Uncontrolled hypertension (>170/100 mmHg) or hypotension (<90/50 mmHg)

NYHA Class IV heart failure

Hereditary degenerative retinal disorders (including retinitis pigmentosa)

History of NAION (relative contraindication -- increased recurrence risk)

Quality Checklist

Good Signs

Film-coated tablets with consistent shape, size, and color (branded Cialis: yellow, almond-shaped)

Clear labeling with manufacturer, lot number, expiration date, and NDC

Blister packaging or sealed bottle with tamper-evident features

Purchased from a licensed pharmacy or verified online pharmacy (VIPPS-accredited)

Generic versions manufactured by reputable pharmaceutical companies with FDA ANDA approval

Warning Signs

Unusually low pricing compared to established generics

Tablets that vary in size, color, or markings within the same batch

Packaging with spelling errors, poor print quality, or missing regulatory information

Sold without requiring a prescription in jurisdictions where one is legally required

Online pharmacies that do not require any medical evaluation

Bad Signs

Tablets that crumble, have an unusual odor, or are discolored

Products sourced from unregulated overseas pharmacies with no quality verification

'Herbal' or 'natural' supplements found to contain undeclared tadalafil

No expiration date, lot number, or manufacturer information on packaging

Counterfeit packaging -- check manufacturer security features (holograms, embossing)

Frequently Asked Questions

Is daily tadalafil better than as-needed sildenafil for erectile dysfunction?

Daily tadalafil (2.5-5mg) provides continuous coverage without timing constraints, while as-needed sildenafil requires planning. Daily tadalafil is better if you want spontaneous sexual activity; as-needed sildenafil is better if you prefer event-based dosing. Both are effective—choose based on your lifestyle preference.

Can I use tadalafil to improve my pumps during workouts?

Tadalafil enhances blood flow and vasodilation through PDE5 inhibition, so users report improved muscle pumps during training and higher blood pressure in muscles. Some athletes dose 12.5-25mg on training days. Results are subjective—blood flow improvement is real, but muscle growth effect is indirect (better nutrient delivery, not direct anabolism).

Is tadalafil safer long-term than sildenafil?

Both have excellent long-term safety profiles with 20+ years of data. Tadalafil's longer half-life and higher PDE5/PDE6 selectivity mean fewer visual side effects, but both can cause headaches, back pain, and vision changes at high doses. Neither is intrinsically safer long-term—choice depends on your dosing preference and side effect tolerance.

Does tadalafil affect my testosterone or hormone levels?

No—tadalafil doesn't suppress testosterone, affect DHT conversion, or interfere with HPTA function. It works purely through vascular effects (cGMP signaling) independent of hormone pathways. Safe to use alongside TRT or during steroid cycles for erectile support without hormonal complications.

References

Comprehensive review of tadalafil 5mg once daily for BPH/LUTS. Demonstrated statistically significant and clinically meaningful improvements in IPSS total score vs placebo across multiple RCTs. Confirmed that daily tadalafil effectively treats both ED and BPH simultaneously in men with comorbid conditions.

Phase II dose-finding study establishing 5mg as the optimal daily dose for BPH/LUTS. Tadalafil 5mg daily produced significant improvements in IPSS at 6 and 12 weeks compared to placebo, with a favorable side effect profile that supported long-term daily dosing.

Meta-analysis of 17 RCTs demonstrating that PDE5 inhibitors including tadalafil significantly improve endothelial function, as measured by flow-mediated dilation, across a range of cardiovascular risk populations. Supports the concept that chronic PDE5 inhibition has vascular protective effects beyond erectile function.

Detailed pharmacological comparison of PDE5 inhibitors. Tadalafil demonstrated unique pharmacokinetics with a half-life of 17.5 hours (vs 3-5 hours for sildenafil and vardenafil), minimal food interaction, and high PDE5/PDE6 selectivity ratio contributing to lower incidence of visual disturbances.

Pooled analysis of pivotal phase III trials demonstrating that tadalafil 10mg and 20mg significantly improved erectile function (IIEF-EF domain scores), intercourse success rates, and overall sexual satisfaction compared to placebo across diverse ED populations including diabetics and post-prostatectomy patients.

Related Peptides

No known pharmacological interaction. BPC-157's effects on angiogenesis and NO system may theoretically complement tadalafil, though clinical data on the combination is lacking.

Disclaimer

This information is for educational and research purposes only. Consult a healthcare professional before use.